Shoreline Biosciences to Present at 2024 Stifel Healthcare Conference
Shoreline Biosciences to Participate at the 2023 Wedbush Pacgrow Healthcare Conference
Shoreline Biosciences to Present Multiple Posters on iPSC-Derived NK Cell Platform at AACR Annual Meeting 2022
San Diego, Calif., March 9, 2022 – Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs)
Shoreline Biosciences Strengthens Senior Management Team With Three Key Hires
San Diego, Calif., February 15, 2022 – Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs)
Shoreline Biosciences To Present At Two Upcoming Investor Conferences
SAN DIEGO, Nov. 23, 2021 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem
Dendreon Pharmaceuticals and Shoreline Biosciences Announce CMC and Manufacturing Alliance to Advance the Future of iPSC Cellular Therapy
– Partnership Focuses on Next Generation Allogeneic Cell Therapies – SEAL BEACH, Calif. & SAN DIEGO, November 4th , 2021 – Dendreon Pharmaceuticals, a commercial-stage
Shoreline Biosciences Announces $140M Financing To Advance Pipeline Of Next Generation Cell Immunotherapies
Financing accelerates the growth of Shoreline’s pipeline of iPSC-based cell immunotherapies for the treatment of seriously ill patients and enables the buildout of smart manufacturing capabilities SAN
Shoreline Biosciences Appoints Scott Forrest, PH.D., as Chief Business Officer
“We’re thrilled to welcome Scott to Shoreline as Chief Business Officer,” said Kleanthis G. Xanthopoulos, Ph.D., Chairman and CEO. “Scott is a highly accomplished executive